DK1412503T3 - Et fusionsprotein - Google Patents

Et fusionsprotein

Info

Publication number
DK1412503T3
DK1412503T3 DK02749112T DK02749112T DK1412503T3 DK 1412503 T3 DK1412503 T3 DK 1412503T3 DK 02749112 T DK02749112 T DK 02749112T DK 02749112 T DK02749112 T DK 02749112T DK 1412503 T3 DK1412503 T3 DK 1412503T3
Authority
DK
Denmark
Prior art keywords
fusion protein
molecule
functional
relates
present
Prior art date
Application number
DK02749112T
Other languages
English (en)
Inventor
Simon Arnett Jones
Nicholas Topley
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff filed Critical Univ Cardiff
Application granted granted Critical
Publication of DK1412503T3 publication Critical patent/DK1412503T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
DK02749112T 2001-08-03 2002-08-02 Et fusionsprotein DK1412503T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119015.6A GB0119015D0 (en) 2001-08-03 2001-08-03 A fusion protein
PCT/GB2002/003581 WO2003014359A2 (en) 2001-08-03 2002-08-02 A fusion protein

Publications (1)

Publication Number Publication Date
DK1412503T3 true DK1412503T3 (da) 2009-04-06

Family

ID=9919793

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02749112T DK1412503T3 (da) 2001-08-03 2002-08-02 Et fusionsprotein

Country Status (13)

Country Link
US (3) US20050064558A1 (da)
EP (1) EP1412503B1 (da)
JP (1) JP4360902B2 (da)
KR (1) KR100870296B1 (da)
AT (1) ATE419362T1 (da)
AU (1) AU2002319524B2 (da)
CA (1) CA2456183C (da)
DE (1) DE60230627D1 (da)
DK (1) DK1412503T3 (da)
ES (1) ES2320862T3 (da)
GB (1) GB0119015D0 (da)
NZ (1) NZ530943A (da)
WO (1) WO2003014359A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026353A2 (en) 2005-08-29 2007-03-08 Technion Research & Development Foundation Ltd. Media for culturing stem cells
US9040297B2 (en) * 2006-08-02 2015-05-26 Technion Research & Development Foundation Limited Methods of expanding embryonic stem cells in a suspension culture
KR20110044992A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
EA019512B1 (ru) * 2008-07-02 2014-04-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Il-6-опосредованная иммунотерапия
JP2010271181A (ja) * 2009-05-21 2010-12-02 Kenji Yamamoto Ｃｃｒ５を標的とする阻害剤の疾病治療効果、予防効果及び副作用を評価する方法
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
US9429463B2 (en) 2013-03-04 2016-08-30 International Road Dynamics, Inc. System and method for measuring moving vehicle information using electrical time domain reflectometry
EP2992898A1 (en) * 2014-09-04 2016-03-09 Klinikum rechts der Isar der Technischen Universität München T-cell adjuvant and its use for therapeutic or prophylactic vaccination

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5250836A (en) * 1989-12-20 1993-10-05 Fujitsu Limited Semiconductor device having silicon-on-insulator structure
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US20040170604A1 (en) * 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
WO2000001731A1 (fr) * 1998-07-06 2000-01-13 Tosoh Corporation Proteine fusionnee avec liaison directe du recepteur il-6 a il-6

Also Published As

Publication number Publication date
EP1412503B1 (en) 2008-12-31
ATE419362T1 (de) 2009-01-15
KR20040049838A (ko) 2004-06-12
KR100870296B1 (ko) 2008-11-25
CA2456183C (en) 2010-01-05
WO2003014359A3 (en) 2003-10-16
AU2002319524B2 (en) 2006-10-12
JP4360902B2 (ja) 2009-11-11
US20050064558A1 (en) 2005-03-24
JP2005502337A (ja) 2005-01-27
DE60230627D1 (de) 2009-02-12
WO2003014359A2 (en) 2003-02-20
US20090252705A1 (en) 2009-10-08
NZ530943A (en) 2005-09-30
GB0119015D0 (en) 2001-09-26
ES2320862T3 (es) 2009-05-29
CA2456183A1 (en) 2003-02-20
US20070172458A1 (en) 2007-07-26
EP1412503A2 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
NO20054223L (no) Antistoffmolekyler som har spesifisitet for human IL-1beta
HUP0303246A2 (hu) Aktív fehérjék fokozott kinyerése
FI963101A0 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
MXPA05010830A (es) Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana.
ATE515514T1 (de) Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
HK1061566A1 (en) Proteins producing an altered immunogenic response and methods of making and using the same
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
EA200801427A1 (ru) Молекулы антитела со специфической активностью в отношении интерлейкина-6 (ил-6) человека
WO2005063820A3 (en) Il-7 fusion proteins
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
PL1641483T3 (pl) Białka fuzyjne
NO20023008D0 (no) Cykliske AMP-spesifikke fosfodiesterase-inhibitorer
DK1412503T3 (da) Et fusionsprotein
EA200400399A1 (ru) Способы лечения легочных заболеваний
WO2003016551A3 (en) Novel salicylic acid-binding protein encoding nucleic acid, sabp2, and methods of use thereof
WO2005035564A3 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
SE0004892D0 (sv) Group 2 allergen specific IgE-Fabs and use thereof
EP1379678A4 (en) HUMAN PROTEASE ISOLATED PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN PROTEASE PROTEINS AND USES THEREOF
EP1395674A4 (en) ISOLATED HUMAN PROTEASE PROTEINS, HUMAN PROTEASE PROTEIN CODING NUCLEIC ACID MOLECULES AND USES THEREOF
WO2001075021A3 (fr) Nouveau polypeptide, proteine humaine associee au transport de glucose 10, et polynucleotide codant pour ce polypeptide
DE60209797D1 (de) Antikörper zur stimulierung der produktion von il-1ra
WO2001075027A3 (fr) Nouveau polypeptide, helicase humaine 13, et polynucleotide codant pour ce polypeptide
WO2001087961A1 (fr) Nouveau polypeptide, proteine pax humaine 11.4, et polynucleotide codant pour ce polypeptide
WO2001079438A3 (fr) Nouveau polypeptide, proteine humaine de liaison 9 d'une proteine precurseur de l'amyloide, et polynucleotide codant pour ce polypeptide
WO2002063013A3 (en) Human acid phosphatase gene